AnaptysBio

Traded on the St. Petersburg Stock Exchange
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications.
AnaptysBio stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

AnaptysBio balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

AnaptysBio cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

AnaptysBio multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

AnaptysBio profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
AnaptysBio assets
AnaptysBio cash flows

AnaptysBio shares

TickerNameTypeNominal valueISINPrice
ANAB:USAnaptysBio, Inc.Common share-US0327241065$21.67
AnaptysBio news
05.05.2022
AnaptysBio's GAAP loss for 3 months of 2022 was $36.255 million, up 99.6% from $18.163 million in the prior year. Revenue decreased 11.59 times to $0.97 million from $11.247 million a year earlier.
Source: {source} pictogram ir.anaptysbio.com
Pictogram next
07.03.2022
AnaptysBio's GAAP loss for 2021 was $57.796 million, up 2.9 times from $19.931 million in the previous year. Revenue decreased 15.8% to $63.175 million from $75 million a year earlier.
Source: {source} pictogram ir.anaptysbio.com
Pictogram next
05.11.2021
AnaptysBio's GAAP loss for 9M 2021 was $25.258 million, down 2.2 times from $53.577 million in the previous year. Revenue increased 4.1 times to $62.164 million from $15 million a year earlier.
Source: {source} pictogram ir.anaptysbio.com
Pictogram next
10.08.2021
AnaptysBio's GAAP loss for 6M 2021 was $18.592 million, down 37.6% from $29.81 million in the previous year. Revenue increased 2.8 times to $41.274 million from $15 million a year earlier.
Source: {source} pictogram ir.anaptysbio.com
Pictogram next
All AnaptysBio news
General information
Company nameAnaptysBio
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address10421 PACIFIC CENTER COURT, SUITE 200 SAN DIEGO CA 92121 858-362-6295
Mailing address10421 PACIFIC CENTER COURT, SUITE 200 SAN DIEGO CA 92121
Websitewww.anaptysbio.com
Information disclosurewww.sec.gov